BACKGROUND: Primary care providers and health systems have prominent roles in guiding effective @entity5 screening. OBJECTIVE: To characterize variation in screening abnormality rates and timely initial follow-up for common @entity5 screening tests. DESIGN: Population-based cohort undergoing screening in 2011, 2012, or 2013 at seven research centers comprising the National @entity5 Institute-sponsored Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium. @entity1 : Adults undergoing mammography with or without digital breast tomosynthesis (n = 97,683 ages 40-75 years), fecal occult blood or fecal immunochemical tests (n = 759,553 ages 50-75 years), or Papanicolaou with or without @entity1082 tests (n = 167,330 ages 21-65 years). INTERVENTION: Breast, colorectal, or cervical @entity5 screening. MAIN MEASURES: Abnormality rates per 1000 screens; percentage with timely initial follow-up (within 90 days, except 9-month window for BI-RADS 3). Primary care clinic-level variation in percentage with screening abnormality and percentage with timely initial follow-up. KEY RESULTS: There were 10,248/97,683 (104.9 per 1000) abnormal @entity0 screens, 35,847/759,553 (47.2 per 1000) FOBT/FIT-positive @entity14 screens, and 13,266/167,330 (79.3 per 1000) @entity5 screens. The percentage with timely follow-up was 93.2 to 96.7 % for breast centers, 46.8 to 68.7   % for colorectal centers, and 46.6 % for the cervical @entity5 screening center (low-grade squamous intraepithelial lesions or higher). The primary care clinic variation (25th to 75th percentile) was smaller for the percentage with an abnormal screen (breast, 8.5-10.3 %; colorectal, 3.0-4.8 %; cervical, 6.3-9.9 %) than for the percentage with follow-up within 90 days (breast, 90.2-95.8 %; colorectal, 43.4-52.0 %; cervical, 29.6-61.4 %). CONCLUSIONS: Variation in both the rate of @entity854 and their initial follow-up was evident across organ sites and primary care clinics. This highlights an opportunity for improving the delivery of @entity5 screening through focused study of @entity1 , provider, clinic, and health system characteristics associated with timely follow-up of @entity854 .

Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'PARTICIPANTS'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['abnormal cervical cancer', 'cancer', 'Cancer'] @entity854 :: ('MESH:D018376', 'Disease') :: ['screening abnormalities'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']
@entity14 :: (MESH:D015179,Disease) :: ['Colorectal Cancer Screening within the PROSPR Consortium']
